Glucagonoma — Pancreatic Alpha-Cell Tumor

Table of Contents

  1. Overview
  2. The 4D Syndrome
  3. Necrolytic Migratory Erythema — The Pathognomonic Rash
  4. Pathophysiology — How Excess Glucagon Causes Multi-System Disease
  5. Laboratory Findings
  6. Diagnosis
  7. Treatment — Surgical Resection
  8. Medical Management and Nutritional Support
  9. Treatment of Metastatic Disease
  10. MEN1 Association
  11. Prognosis
  12. Key Research Papers
  13. Connections
  14. Featured Videos

Overview

Glucagonoma is a rare pancreatic neuroendocrine tumor (PNET) arising from the alpha cells of the islets of Langerhans. Alpha cells normally secrete glucagon to raise blood glucose during fasting; in glucagonoma, glucagon is secreted autonomously and in excess, producing a characteristic multi-system syndrome driven by unrelenting glucagon excess. The incidence is less than 1 per million per year — glucagonoma stands among the rarest of the functional PNETs, rarer even than VIPoma or somatostatinoma.

Several features distinguish glucagonoma from other functional PNETs and make it both clinically challenging and surgically demanding. First, glucagonoma is almost always malignant — unlike insulinoma where 90% are benign, glucagonomas are malignant in 50–80% of cases. Second, they are large at diagnosis, often measuring 5–10 cm at the time of detection (a stark contrast to insulinoma, where 90% are under 2 cm, because the profound hypoglycemia of insulinoma drives rapid diagnosis). Third, they arise predominantly in the body and tail of the pancreas, unlike gastrinoma which clusters in the gastrinoma triangle at the head. Fourth, liver metastases are present in 50–80% of patients at diagnosis, reflecting the long latency between tumor inception and clinical recognition — the slow-developing skin rash and mild diabetes are easily misattributed for months to years before the correct diagnosis is made.

The clinical history of glucagonoma begins with Becker and colleagues in 1942, who described the association between a distinctive skin rash and a pancreatic tumor. McGavran coined the term "glucagonoma syndrome" in 1966, linking the skin findings, diabetes, and wasting to autonomous glucagon hypersecretion from an alpha-cell tumor. The landmark 1974 Lancet paper by Mallinson and colleagues established the full clinical picture in a cohort of nine patients, cementing glucagonoma syndrome as a defined endocrine entity.

Back to Table of Contents

The 4D Syndrome

Classic teaching for glucagonoma syndrome employs the mnemonic of the 4 Ds, capturing the major clinical manifestations produced by autonomous glucagon hypersecretion. Recognizing this constellation is the key to avoiding the diagnostic delays — averaging 2–4 years in published series — that characterize this disease.

D1 — Dermatitis (Necrolytic Migratory Erythema): The hallmark and most distinctive feature of glucagonoma syndrome. A cyclic, bronze-red, migrating rash with blistering and crusted erosions, predominantly in intertriginous areas. It is pathognomonic when combined with hyperglucagonemia. Detailed discussion in the dedicated section below. Present in 70–80% of patients at diagnosis and often the finding that ultimately leads to the correct diagnosis.

D2 — Diabetes: Mild to moderate hyperglycemia due to glucagon-driven gluconeogenesis and glycogenolysis. The diabetes is typically Type 2-like in severity — fasting glucose of 150–250 mg/dL — and rarely leads to diabetic ketoacidosis. This is mechanistically important: unlike Type 1 diabetes where insulin is absent, in glucagonoma insulin is present (beta cells are intact) but overwhelmed by the relentless glucagon signal. Ketoacidosis does not develop because residual insulin suppresses ketogenesis. Patients often receive a diagnosis of Type 2 diabetes mellitus and are treated for years before the correct underlying cause is identified.

D3 — Deep Vein Thrombosis: Venous thromboembolic events — deep vein thrombosis (DVT) and pulmonary embolism (PE) — occur in 15–35% of patients with glucagonoma syndrome. Pulmonary embolism is one of the most significant causes of preventable morbidity and mortality in this disease. The mechanism is incompletely understood but likely involves a combination of hyperglucagonemia's effects on the coagulation cascade, nutritional deficiencies (particularly hypoaminoacidemia) affecting clotting factor synthesis, reduced mobility from constitutional symptoms, and possibly direct tumor-associated procoagulant effects. Anticoagulation is a critical component of management and must not be overlooked in any patient with glucagonoma.

D4 — Depression / Diarrhea / weight loss (and more): Psychiatric manifestations including depression, irritability, and anxiety occur in up to 25% of patients — a reflection of the profound nutritional and metabolic derangement caused by chronic glucagon excess. Diarrhea occurs in some patients. Significant weight loss and cachexia result from glucagon-driven catabolism of amino acids and adipose tissue. Additional features captured in the broader syndrome include:

Some authors extend the mnemonic to a 5th D — Diagnosis delay, reflecting the typical 2–4 year lag from symptom onset to correct identification. The individual components (diabetes, skin rash, weight loss, depression) each masquerade as common conditions and rarely trigger the synthesis needed to diagnose this rare tumor.

Back to Table of Contents

Necrolytic Migratory Erythema — The Pathognomonic Rash

Necrolytic Migratory Erythema (NME) is the most clinically distinctive and diagnostically important feature of glucagonoma syndrome. Every clinician should be able to recognize it, because NME is often the first presentation that leads — if correctly identified — to the life-saving diagnosis of a potentially curable tumor.

Description and behavior: NME presents as cyclic, erythematous (bronze-red) plaques that begin as small papules or vesicles, progress to superficial bullae (blisters), which then rupture, leaving crusted erosions with central clearing as the active margin of the rash migrates outward — hence "migratory." The lesions heal in one area over days to weeks, leaving hyperpigmented scars, while simultaneously new lesions erupt at adjacent or distant sites. This cycling, migrating quality is highly characteristic. Individual lesions may itch or burn and are often secondarily infected with Candida or Staphylococcus.

Distribution: NME shows a strong predilection for intertriginous and friction-prone areas — the groin, perineum, perianal region, lower abdomen, lower extremities (especially the shins), perioral skin, and fingertips. The pattern reflects areas of highest epidermal stress, consistent with the mechanism of amino acid depletion impairing skin barrier repair.

Histology: Skin biopsy from the active leading edge of a lesion shows superficial epidermal necrosis with vacuolated (ballooned) keratinocytes in the upper epidermis. This finding is characteristic but not entirely specific — it can also be seen in other hypoaminoacidemic states. The biopsy must come from an active lesion margin, not the healed center.

Mechanism — Hypoaminoacidemia: The root cause of NME is amino acid depletion of the skin. Glucagon drives gluconeogenesis by consuming circulating amino acids — particularly branched-chain amino acids (valine, leucine, isoleucine) and aromatic amino acids — as glucose precursors. Plasma amino acid levels fall dramatically across all classes. The epidermis requires amino acids for ongoing protein synthesis, keratinocyte differentiation, and maintenance of the skin's barrier function. When the amino acid supply falls below a critical threshold, the epidermis cannot sustain its normal renewal cycle, leading to the cyclic necrotic breakdown seen in NME.

The strongest evidence supporting hypoaminoacidemia as the mechanism comes from a clinically important observation: NME resolves dramatically and rapidly with intravenous amino acid infusions (as part of total parenteral nutrition). Skin lesions that have been present for months can clear visibly within 2–4 weeks of IV amino acid supplementation — even before surgical removal of the tumor. This preoperative intervention has become a standard part of glucagonoma management. Additionally, NME can occur in other hypoaminoacidemic states (severe cirrhosis with malnutrition, malabsorption syndromes, celiac disease) in the complete absence of glucagonoma — confirming that amino acid depletion, not glucagon directly, damages the skin. Zinc deficiency contributes as a co-factor, since zinc is required for normal epidermal healing and turnover, and zinc is often depleted in glucagonoma syndrome.

Clinical pearl — Diagnostic recognition: A patient presenting with a bizarre, cyclic, migrating skin rash in intertriginous areas, combined with diabetes and weight loss, should prompt immediate measurement of fasting plasma glucagon. The diagnosis of NME is frequently missed for years — dermatologists may label it psoriasis, eczema, dermatitis herpetiformis, seborrheic dermatitis, pemphigus, or contact dermatitis. The migratory and cycling quality, combined with the metabolic context, is the key discriminating feature. When a dermatologist biopsies NME and sees epidermal necrosis, "think pancreas" is the appropriate next thought.

Back to Table of Contents

Pathophysiology — How Excess Glucagon Causes Multi-System Disease

Understanding glucagonoma syndrome requires understanding the three major metabolic effects of glucagon and how each is amplified to pathological levels by autonomous tumor secretion.

1. Glycogenolysis and Gluconeogenesis → Hyperglycemia and Diabetes: Glucagon's primary physiological role is to raise blood glucose during fasting by signaling the liver to break down stored glycogen (glycogenolysis) and to synthesize new glucose from amino acid precursors (gluconeogenesis). In glucagonoma, this signal is continuous and unregulated. The liver responds with sustained glucose output → persistent fasting hyperglycemia → clinical diabetes. The diabetes is typically moderate because residual beta cell function produces some insulin, but the beta cells cannot overcome the constant glucagon signal. Additionally, glucagon exerts a direct paracrine inhibitory effect on adjacent beta cells within the islets, suppressing insulin secretion and further amplifying hyperglycemia. Glucagon also promotes insulin resistance at peripheral tissues through mechanisms that remain incompletely characterized.

2. Amino Acid Catabolism → Hypoaminoacidemia → NME, Weight Loss, Stomatitis, and Anemia: The most fundamental and multisystem consequence of glucagon excess is the relentless consumption of circulating amino acids as gluconeogenic substrates. Plasma amino acid levels fall across all classes — branched-chain amino acids (valine, leucine, isoleucine), aromatic amino acids (phenylalanine, tyrosine, tryptophan), and others. This hypoaminoacidemia has cascading consequences: the skin loses its supply of building blocks for epidermal protein synthesis → NME develops; mucous membranes lose their renewal supply → stomatitis and glossitis; the bone marrow loses substrates for hemoglobin synthesis and red cell production → normocytic anemia; muscle protein is broken down to supply amino acids → muscle wasting and weight loss. The constitutional cachexia of glucagonoma is among the most severe seen in any endocrine tumor and directly reflects this amino acid depletion.

3. Lipolysis → Fat Loss and Cachexia: Glucagon activates adipose tissue lipolysis through hormone-sensitive lipase, releasing free fatty acids into the circulation. These fatty acids are mobilized for hepatic beta-oxidation and ketone body formation (though full ketoacidosis is prevented by residual insulin). The clinical result is progressive loss of adipose tissue, contributing to the severe cachexia. Combined with the muscle wasting from amino acid catabolism, patients with advanced glucagonoma can lose 20–30% of body weight.

Coagulation effects: Glucagon has incompletely characterized effects on the coagulation cascade. Hypoaminoacidemia may deplete clotting factor synthesis (factors are proteins requiring amino acids for production). Nutritional depletion, reduced mobility, and possible direct tumor effects on the vascular endothelium all contribute to the markedly elevated thromboembolic risk that defines glucagonoma management.

Cardiac effects: Glucagon has positive inotropic and chronotropic effects on the heart (exploited clinically in beta-blocker overdose treatment). Chronic glucagon excess may contribute to cardiac remodeling, though clinical cardiomyopathy is not a dominant feature of the syndrome.

Back to Table of Contents

Laboratory Findings

The laboratory profile of glucagonoma is highly characteristic and, when interpreted in the correct clinical context, is essentially diagnostic. Systematic measurement of the key analytes below should follow recognition of the clinical syndrome.

Plasma Glucagon (fasting): The central diagnostic test. Normal fasting glucagon is less than 150 pg/mL. Values greater than 500 pg/mL are strongly suggestive of glucagonoma. Values greater than 1000 pg/mL are essentially diagnostic in the appropriate clinical context. Important caveats: moderately elevated glucagon levels (150–500 pg/mL) can occur in non-tumor states including physiological stress, prolonged fasting, renal failure, cirrhosis, and diabetic ketoacidosis — these states elevate glucagon through reactive mechanisms rather than autonomous secretion, and they lack the full clinical syndrome. The diagnosis requires both the biochemical elevation and the clinical context.

Fasting Plasma Amino Acid Panel: Hypoaminoacidemia across multiple amino acid classes is characteristic of glucagonoma and highly useful diagnostically. All or most amino acids are depleted — particularly branched-chain amino acids and aromatic amino acids. This is not a routine test in most clinical algorithms but should be measured when glucagonoma is suspected; it provides both diagnostic and therapeutic guidance (replacement targets).

Fasting Blood Glucose and HbA1c: Fasting glucose typically runs 150–250 mg/dL. HbA1c is elevated, reflecting chronic hyperglycemia. The pattern mimics Type 2 diabetes but is distinguished by context (weight loss, NME, elevated glucagon).

Complete Blood Count: Normochromic, normocytic anemia is the typical pattern — reflecting nutritional suppression of erythropoiesis rather than iron deficiency or hemolysis. Iron studies, B12, and folate are typically normal.

Serum Zinc: Often low; zinc deficiency co-contributes to NME and impairs wound healing. Replacement is part of treatment.

Liver Function Tests: May be elevated if hepatic metastases are present. A patient with a large right-lobe tumor burden will have elevated alkaline phosphatase, GGT, and possibly bilirubin.

Chromogranin A: A general neuroendocrine tumor marker, elevated in most functional and non-functional PNETs. Useful for diagnosis and monitoring treatment response but not specific to glucagonoma.

Skin Biopsy: Biopsy from the active leading edge (not healed center) of an NME lesion shows superficial epidermal necrosis with vacuolated keratinocytes in the upper epidermis. The pathologist should be asked specifically to evaluate for NME; routine inflammatory skin disease panels may not capture this pattern.

Back to Table of Contents

Diagnosis

Glucagonoma diagnosis requires synthesis of clinical recognition, biochemical confirmation, and imaging characterization — with biopsy confirming the PNET diagnosis and histological grade.

Step 1 — Clinical recognition: The triad of NME + diabetes + weight loss in a middle-aged adult should immediately raise suspicion. Any one of these in isolation is common; the combination is rare and should trigger glucagon measurement without delay. A history of migratory rash misdiagnosed as psoriasis or eczema for years should heighten suspicion. Clinicians who see patients with unexplained normocytic anemia + diabetes + constitutional symptoms should consider glucagonoma in the differential.

Step 2 — Biochemical confirmation: Fasting plasma glucagon greater than 500 pg/mL in the appropriate clinical context constitutes glucagonoma until proven otherwise. Send simultaneously: fasting glucagon, fasting glucose, fasting plasma amino acid panel, chromogranin A, zinc, CBC, and liver function tests. The combination of markedly elevated glucagon + hypoaminoacidemia + normocytic anemia is nearly pathognomonic.

Step 3 — Cross-sectional imaging: CT of the abdomen with triphasic contrast (arterial, portal venous, and delayed phases) is typically the first imaging modality. Glucagonomas are usually large (5–10 cm) at diagnosis and readily visible in the pancreatic body or tail. Contrast enhancement pattern is variable. Liver metastases are typically multiple and hypervascular. Unlike insulinoma where CT frequently misses small tumors, glucagonoma is usually obvious on CT.

Step 4 — Somatostatin receptor imaging: 68Ga-DOTATATE PET/CT is now the staging standard for functional and non-functional PNETs. Glucagonomas express somatostatin receptors (sst2) in the majority of cases, making them 68Ga-DOTATATE-avid. This scan detects: primary tumor, regional lymph nodes, liver metastases, bone metastases, and peritoneal disease. It also predicts eligibility for PRRT (177Lu-DOTATATE therapy), which requires somatostatin receptor positivity.

Step 5 — MRI: MRI of the abdomen with liver-specific contrast (gadoxetate) provides superior characterization of liver metastases — useful for surgical planning when liver resection or ablation is being considered.

Step 6 — Tissue biopsy and histology: Core biopsy of the primary tumor or a liver metastasis confirms the PNET diagnosis. Immunohistochemistry is positive for: synaptophysin, chromogranin A, and glucagon. Ki-67 index assigns tumor grade: G1 (well-differentiated, Ki-67 less than 2%), G2 (Ki-67 2–20%), or G3 (poorly differentiated, Ki-67 above 20%). Grade profoundly influences treatment strategy and prognosis — G1/G2 tumors are managed with SSAs, everolimus, sunitinib, and PRRT; G3 tumors often require platinum-based chemotherapy.

Differential diagnosis: Other causes of elevated glucagon include physiological stress, prolonged fasting, renal failure (glucagon cleared by kidney), cirrhosis, and diabetic ketoacidosis. These states lack the full clinical syndrome and rarely produce glucagon levels above 500 pg/mL. NME-like rashes can occur in cirrhosis with severe malnutrition, malabsorption, and pellagra (niacin deficiency) — all sharing the common pathophysiology of hypoaminoacidemia — but the markedly elevated glucagon distinguishes glucagonoma.

Back to Table of Contents

Treatment — Surgical Resection

Surgical resection is the only potential cure for glucagonoma and the most effective means of reducing tumor burden and glucagon levels even in metastatic disease. The surgical approach depends on tumor location, extent of disease, and patient fitness.

Curative resection: A minority of patients (20–50%) present with localized, potentially resectable disease. For tumors in the body and tail of the pancreas (the predominant location), the standard operation is distal pancreatectomy with splenectomy. Spleen-preserving distal pancreatectomy may be attempted for smaller tumors distant from the splenic vessels, but oncological principles generally favor splenectomy given the malignant nature of these tumors. For the uncommon head-of-pancreas glucagonoma, a Whipple procedure (pancreaticoduodenectomy) is required. Regional lymphadenectomy is included in all resections. Five-year survival after complete (R0) resection is 50–70%.

Cytoreductive surgery (debulking): Even when liver metastases are present and cure is not possible, surgical debulking plays an important role in glucagonoma management — more so than in many other cancers. Reducing tumor mass by 90% or more can dramatically lower circulating glucagon levels, leading to resolution of NME, improvement in diabetes, weight stabilization, and improved quality of life. The goal is maximum cytoreduction consistent with patient safety. Simultaneous liver resection for resectable liver metastases is performed when technically feasible.

Preoperative preparation — Critical and often overlooked: Patients with glucagonoma who reach the operating room unprepared are at greatly elevated risk of wound complications, poor healing, and perioperative mortality. Systematic preoperative preparation over 2–4 weeks should include:

Back to Table of Contents

Medical Management and Nutritional Support

Medical management of glucagonoma syndrome addresses both the hormonal excess (reducing glucagon secretion or its effects) and the metabolic consequences (replacing depleted nutrients). These interventions are essential regardless of whether surgery is performed.

Amino Acid Infusions and Nutritional Support: The most dramatic and rapid intervention for NME and constitutional symptoms. Intravenous TPN containing a generous amino acid load (1.5–2 g/kg/day protein equivalent) replenishes the depleted amino acid pool. NME begins to clear within 1–2 weeks of initiation and can resolve nearly completely within 4–6 weeks. This is both therapeutically beneficial and diagnostically confirming — rapid NME resolution with amino acid infusions strongly supports glucagonoma as the cause. Oral high-protein, high-calorie supplementation (30–35 kcal/kg/day, 1.5–2 g/kg/day protein) is continued long-term. Commercial protein supplements (whey, casein, mixed amino acid formulas) are helpful for patients who can tolerate oral feeding.

Zinc Supplementation: Zinc deficiency contributes to the NME rash, impairs wound healing, and suppresses immune function. Oral zinc sulfate 220 mg three times daily provides adequate supplementation in most patients. Serum zinc levels should be monitored and supplementation adjusted accordingly. Topical zinc oxide applied to active NME lesions can also accelerate local healing.

Somatostatin Analogs (Octreotide LAR / Lanreotide): Long-acting somatostatin analogs are the cornerstone of medical management for glucagonoma. Somatostatin receptors (predominantly sst2) on glucagonoma cells respond to pharmacological stimulation by markedly reducing glucagon secretion. Clinical effects include: improvement in NME, reduction in hyperglycemia, reduction in diarrhea, weight stabilization, and often improvement in constitutional symptoms. Monthly depot injections (Octreotide LAR 20–30 mg IM monthly, or Lanreotide autogel 90–120 mg subcutaneous monthly) are the standard regimen. Beyond symptom control, somatostatin analogs have antiproliferative effects in well-differentiated PNETs — the CLARINET trial established lanreotide's ability to extend PFS in non-functioning gastroenteropancreatic NETs, and SSA therapy is the first-line treatment for both symptom control and tumor growth stabilization in glucagonoma.

Insulin Therapy: Hyperglycemia is managed with insulin, usually a basal-bolus regimen. Oral antidiabetic agents are less effective in glucagonoma diabetes because the primary defect is glucagon-driven hepatic glucose output rather than insulin deficiency per se. After surgical debulking or with effective medical glucagon suppression, insulin requirements may decrease substantially.

Anticoagulation: Given the 15–35% rate of DVT and PE in glucagonoma syndrome, prophylactic anticoagulation with low molecular weight heparin (LMWH) is recommended for most patients. If DVT or PE is diagnosed, therapeutic anticoagulation is initiated and continued long-term. Direct oral anticoagulants (DOACs) are increasingly used in oncology patients as an alternative to LMWH. The risk of thromboembolic events persists even with good hormonal control and must be managed independently.

Topical Wound Care: NME lesions, particularly when secondarily infected, require local wound care: gentle cleansing, barrier moisturizers, zinc oxide creams, and antifungal treatment if Candida superinfection is present. Avoidance of occlusive dressings and friction-producing clothing in affected areas is helpful. With effective systemic treatment (amino acids, SSAs, glucagon control), topical care is supportive rather than definitive.

Back to Table of Contents

Treatment of Metastatic Disease

The majority of glucagonoma patients present with or eventually develop hepatic and distant metastases. A rapidly expanding toolkit of systemic and liver-directed therapies has transformed the landscape of metastatic PNET management over the past two decades, with meaningful improvements in progression-free and overall survival.

Everolimus (RAD001) — mTOR inhibition: Everolimus, an oral mTOR inhibitor, was evaluated in the pivotal RADIANT-3 trial (Yao et al., N Engl J Med 2011; PMID 21306238), which enrolled 410 patients with progressive advanced pancreatic NETs. Everolimus extended median PFS to 11.0 months versus 4.6 months with placebo — a 65% reduction in the risk of progression or death. The drug is FDA-approved for progressive, well-differentiated, non-functional advanced pNETs and is used for functional tumors including glucagonoma. Common side effects include stomatitis, infections, rash, fatigue, and metabolic effects (hyperglycemia, hyperlipidemia).

Sunitinib — VEGFR inhibition: Sunitinib, an oral multi-targeted tyrosine kinase inhibitor (VEGFR, PDGFR, c-Kit), was evaluated in a phase 3 trial (Raymond et al., N Engl J Med 2011; PMID 21306237) in 171 patients with progressive well-differentiated pNETs. Sunitinib extended median PFS to 11.4 months versus 5.5 months with placebo and also showed an overall survival benefit. FDA-approved for progressive well-differentiated pNETs. Common toxicities: hypertension, fatigue, diarrhea, hand-foot syndrome, neutropenia.

PRRT — 177Lu-DOTATATE (Lutathera): Peptide receptor radionuclide therapy delivers targeted radiation directly to somatostatin receptor-expressing tumor cells. The landmark NETTER-1 trial (Strosberg et al., N Engl J Med 2017; PMID 28076709) demonstrated that 177Lu-DOTATATE extended median PFS to 28.4 months versus 8.5 months with high-dose octreotide in patients with advanced midgut NETs expressing somatostatin receptors. FDA approved in 2018 for gastroenteropancreatic NETs. Glucagonomas typically express somatostatin receptors (confirmed by 68Ga-DOTATATE PET positivity) and are therefore PRRT candidates. The practical requirement is adequate uptake on 68Ga-DOTATATE PET. PRRT is particularly attractive for patients with high tumor burden and multiple liver metastases.

Liver-Directed Therapy: For patients with dominant hepatic metastases, locoregional liver-directed therapies can reduce tumor burden and glucagon levels without systemic toxicity. Options include: hepatic artery chemoembolization (TACE) using drug-eluting beads loaded with doxorubicin or streptozocin; bland embolization (without chemotherapy, exploiting the liver's dual blood supply to deprive tumor of arterial input); radioembolization (90Y-microspheres); and thermal ablation (radiofrequency or microwave) for smaller, accessible lesions. These therapies can achieve dramatic reductions in liver tumor burden and corresponding falls in glucagon levels with improvement in NME and diabetes.

Streptozocin-Based Chemotherapy: Streptozocin (STZ) combined with doxorubicin or 5-fluorouracil was the historical standard for advanced pNETs and remains relevant for poorly differentiated tumors or rapidly progressive disease. Response rates of 35–45% have been reported in historical series, though duration of response is often limited.

Temozolomide ± Capecitabine (TEMCAP): The combination of temozolomide and capecitabine has emerged as an active regimen for well-differentiated pNETs, particularly those with high MGMT methylation (a biomarker of alkylating agent sensitivity). Retrospective studies report response rates of 30–70% in selected patients. Toxicity is generally manageable. Biomarker-selected use of this regimen is an active area of clinical research.

Back to Table of Contents

MEN1 Association

Multiple Endocrine Neoplasia Type 1 (MEN1) is an autosomal dominant syndrome caused by loss-of-function mutations in the MEN1 gene encoding menin, a tumor suppressor. MEN1 produces a triad of parathyroid adenomas (95% of patients), pituitary adenomas (30–40%), and pancreatic neuroendocrine tumors (30–80%). Among the pancreatic NETs in MEN1, insulinoma occurs in approximately 10% and gastrinoma in 40% — these are the dominant functional tumors. Glucagonoma is uncommon in MEN1, occurring in only 3–5% of MEN1 patients.

When glucagonoma does occur in the MEN1 context, it tends to present with clinical features similar to sporadic glucagonoma — NME, diabetes, weight loss — though MEN1-associated tumors may be identified at a somewhat smaller size because MEN1 patients are under active pancreatic surveillance. MEN1-associated glucagonomas are often multiple within the pancreas, consistent with the multi-focal tumor development seen across the MEN1-affected gland.

Any patient diagnosed with glucagonoma without an obvious sporadic cause should undergo systematic MEN1 workup: serum calcium and PTH (to detect primary hyperparathyroidism, the most penetrant MEN1 manifestation), prolactin and IGF-1 (pituitary adenomas), and fasting gastrin (for co-existing gastrinoma). Genetic testing for germline MEN1 mutation should be offered. A positive MEN1 diagnosis changes management substantially — family members require cascade genetic testing and screening, and the surgical approach to pancreatic disease in MEN1 is more conservative (given the diffuse nature of disease) than in sporadic glucagonoma.

The co-occurrence of gastrinoma and glucagonoma in the same MEN1 patient has been described in case reports — a reminder that MEN1 pancreatic NETs can secrete multiple hormones and that the clinical syndrome in a given patient may reflect combined hormone excess.

Back to Table of Contents

Prognosis

The prognosis of glucagonoma is heavily dependent on the stage at diagnosis, histological grade (Ki-67), and the degree of resectability. Overall outcomes have improved significantly over the past two decades with the advent of octreotide therapy, mTOR inhibitors, sunitinib, and PRRT.

Localized, resectable disease: Five-year survival is 50–70% for patients who undergo complete (R0) resection of localized disease. Surgery may be curative, or may provide long-term disease control with delayed recurrence. These patients are the minority — only 20–50% of glucagonoma patients present without distant metastases at diagnosis.

Metastatic disease: For the majority who present with liver metastases, 5-year survival has historically been reported at 20–30%. With modern systemic therapy (SSAs, everolimus, sunitinib, PRRT) and liver-directed therapies, median overall survival in well-differentiated (G1/G2) metastatic pNETs now exceeds 5 years in many series. The indolent biology of G1/G2 PNETs — even when metastatic — allows years of disease control with sequential therapies.

Cause of death: The most common causes of death in glucagonoma are hepatic failure from progressive replacement of the liver parenchyma by metastatic tumor, cachexia and constitutional failure from uncontrolled glucagon excess, and thromboembolic events (pulmonary embolism). The NME skin disease, while severe and disfiguring, is not itself life-threatening — it serves as a marker of the underlying tumor activity and resolves dramatically with effective glucagon control.

Prognostic factors: Liver tumor burden (extent of hepatic replacement) is the strongest predictor of survival. Ki-67 grade is crucial — G1 tumors (Ki-67 less than 2%) behave very differently from G3 tumors (Ki-67 above 20%), which carry a far worse prognosis and require chemotherapy rather than targeted therapy. Resectability of the primary tumor confers a survival advantage even when complete cure is not achieved. Somatostatin receptor expression (positive 68Ga-DOTATATE uptake) is both prognostically favorable (indicating more differentiated tumor biology) and therapeutically predictive (eligibility for PRRT).

Back to Table of Contents

Key Research Papers

  1. McGavran MH et al. A glucagon-secreting alpha-cell carcinoma of the pancreas. N Engl J Med. 1966. PMID 5934859
  2. Mallinson CN et al. A glucagonoma syndrome. Lancet. 1974. PMID 4133605
  3. Wermers RA et al. The glucagonoma syndrome. Clinical and pathologic features in 21 patients. Medicine. 1996. PMID 8979158
  4. van Beek AP et al. The glucagonoma syndrome and necrolytic migratory erythema: a clinical review. Eur J Endocrinol. 2004. PMID 15461592
  5. Norton JA et al. Surgical management of hyperinsulinism in the multiple endocrine neoplasia type 1 syndrome. Surgery. 1999. PMID 10334152
  6. Yao JC et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011. PMID 21306238
  7. Raymond E et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011. PMID 21306237
  8. Strosberg J et al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017. PMID 28076709
  9. Eldor R et al. Glucagonoma and the glucagonoma syndrome — cumulative experience with an elusive endocrine tumour. Clin Endocrinol. 2011. PMID 21371090
  10. Kindmark H et al. Endocrine pancreatic tumors with glucagon hypersecretion. A retrospective study of 23 cases. Med Oncol. 2007. PMID 17934191
  11. Stacpoole PW. The glucagonoma syndrome: clinical features, diagnosis, and treatment. Endocr Rev. 1981. PMID 6117121
  12. Yao JC et al. One hundred years after carcinoid: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008. PMID 18626005

PubMed topic search: Glucagonoma syndrome | Necrolytic migratory erythema | Pancreatic neuroendocrine tumor treatment

Back to Table of Contents

Connections

Back to Table of Contents